Menu
/REGISTER
Montecito
Nixon Peabody
Chase
Bank of America
Loading...
You are here:  Home  >  Central Coast Health Watch  -  Page 85

Sansum Clinic
Latest

Corporate social responsibility on hold when it comes to outrageous drug prices

By   /  Thursday, November 19th, 2015  /  Central Coast Health Watch, Op/Eds  /  Comments Off on Corporate social responsibility on hold when it comes to outrageous drug prices

Imagine you just went to your local pharmacy and were told that the cost of a life-saving drug was $22,500 for 30 tablets to treat AIDS or another infectious disease. Well, if you need the drug Daraprim, that is what you would have to pay. Turing Pharmaceuticals purchased the right to Darprim this past August Read More →

Read More →
Latest

European regulators approve Amgen cancer drug Kyprolis

By   /  Thursday, November 19th, 2015  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on European regulators approve Amgen cancer drug Kyprolis

Thousand Oaks-based Amgen scored another major victory Nov. 19. European regulators approved experimental drug Kyprolis on Thursday for patients who have received at least one prior treatment for multiple-myeloma. Kyprolis was the cornerstone of Amgen’s $10.4 billion buyout of Onyx Pharmaceuticals in 2013. Multiple-myeloma is a form of blood cancer that forms in plasma cells Read More →

Read More →
Latest

French Hospital Medical Center unveils educational facility

By   /  Tuesday, November 17th, 2015  /  Central Coast, Central Coast Health Watch, Latest news, Top Stories  /  Comments Off on French Hospital Medical Center unveils educational facility

  French Hospital Medical Center has taken the wraps off an 18,000-square-foot health and education facility it hopes will forge closer ties between the hospital and higher education in San Luis Obispo. With about 200 business and community leaders standing by, CEO Alan Iftinik unveiled the Copeland Health Education Pavilion. Iftinik said the building, which Read More →

Read More →
Latest

Goleta-based Sientra’s third quarter revenues down

By   /  Monday, November 16th, 2015  /  Central Coast Health Watch, Earnings, Latest news, Tri-County Public Companies  /  Comments Off on Goleta-based Sientra’s third quarter revenues down

Sientra Inc. sales were down 6.9 percent in the third quarter of 2015 but the results were largely unaffected by recent pandemonium at the company. The Goleta-based company reported third quarter results on Nov. 16 for the quarter that ended on Sept. 30, just one week after European regulators pulled products made by Sientra’s Brazilian Read More →

Read More →
Latest

Goleta breast implant maker Sientra shakes up C-Suite

By   /  Thursday, November 12th, 2015  /  Central Coast Health Watch, Latest news, South Coast, Top Stories, Tri-County Public Companies  /  Comments Off on Goleta breast implant maker Sientra shakes up C-Suite

  The writing was on the wall at Sientra. On Nov. 12, the company’s top executives took the fall. The embattled Goleta-based breast implant manufacturer cleaned house Thursday afternoon. Sientra founder and CEO Hani Zeini stepped down as CEO and he will be replaced by industry veteran Jeffrey Nugent. Nicholas Simon also resigned as chairman Read More →

Read More →
Latest

Inogen’s third quarter earnings beat Wall Street expectations

By   /  Wednesday, November 11th, 2015  /  Central Coast Health Watch, Earnings, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Inogen’s third quarter earnings beat Wall Street expectations

  Inogen, a Goleta-based maker of direct-to-consumer respiratory products, beat analyst estimates for revenue when the company released third quarter earnings on Nov. 10. Revenues were up 38.7 percent from $29.4 million during the third quarter of last year to $40.8 million this year. Analysts had predicted revenues of $37 million. Inogen also reported adjusted Read More →

Read More →
Latest

FDA to review Amgen’s new kidney disease dug

By   /  Friday, November 6th, 2015  /  Central Coast Health Watch, East Ventura County, Latest news  /  Comments Off on FDA to review Amgen’s new kidney disease dug

Thousand Oaks-based biotech giant Amgen announced on Nov. 6 that the Food and Drug Administration will review a new treatment for patients with chronic kidney disease. The new drug, Etelcalcetide, works by suppressing the secretion of a parathyroid hormone. The drug is administered intravenously three times per week at the end of a dialysis session. Read More →

Read More →